Float Short %

6.14

Margin Of Safety %

Put/Call OI Ratio

0.14

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

0.21

Price

15.2

Target Price

20.86

Analyst Recom

1.25

Performance Q

10.55

Upside

-192.1%

Beta

2.2

Ticker: ADPT

18 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-01-23	ADPT	18.55	0.24	0.00	2340
2026-01-26	ADPT	19.12	0.18	0.04	2928
2026-01-27	ADPT	19.24	0.18	0.00	2911
2026-01-28	ADPT	18.5	0.18	0.25	2916
2026-01-29	ADPT	18.38	0.18	0.00	2923
2026-01-30	ADPT	18.5	0.18	0.00	2973
2026-02-02	ADPT	18.39	0.18	0.00	2973
2026-02-03	ADPT	18.51	0.18	0.01	2975
2026-02-05	ADPT	16.43	0.18	0.38	3169
2026-02-09	ADPT	15.87	0.18	0.23	3178
2026-02-10	ADPT	15.65	0.18	0.00	3179
2026-02-11	ADPT	15.62	0.18	0.00	3179
2026-02-12	ADPT	15.53	0.17	0.00	3155
2026-02-13	ADPT	16.03	0.18	0.06	3061
2026-02-17	ADPT	15.81	0.17	5.78	3092
2026-02-18	ADPT	15.88	0.15	1.78	3040
2026-02-19	ADPT	16.04	0.16	0.05	3074
2026-02-20	ADPT	15.2	0.14	0.00	3032
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

18 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-01-23	ADPT	18.53	21.5	-	-0.49
2026-01-26	ADPT	19.12	21.5	-	-0.49
2026-01-27	ADPT	19.23	19.7	-	-0.49
2026-01-28	ADPT	18.51	19.7	-	-0.49
2026-01-29	ADPT	18.39	19.7	-	-0.49
2026-01-30	ADPT	18.50	19.7	-	-0.49
2026-02-02	ADPT	18.42	19.7	-	-0.49
2026-02-03	ADPT	18.51	19.7	-	-0.49
2026-02-04	ADPT	17.30	19.7	-	-0.49
2026-02-05	ADPT	16.45	19.7	-	-0.49
2026-02-06	ADPT	15.78	19.7	-	-0.49
2026-02-09	ADPT	15.86	9.0	-	-0.58
2026-02-10	ADPT	15.65	18.6	-	-0.49
2026-02-11	ADPT	15.63	17.9	-	-0.50
2026-02-12	ADPT	15.53	17.9	-	-0.50
2026-02-13	ADPT	16.04	19.3	-	-0.48
2026-02-17	ADPT	15.80	19.3	-	-0.48
2026-02-18	ADPT	15.89	19.3	-	-0.48
2026-02-19	ADPT	16.05	19.3	-	-0.48
2026-02-20	ADPT	15.20	19.3	-	-0.48
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-01-23	ADPT	-20.04	-1.37	5.96
2026-01-26	ADPT	-20.04	-1.58	5.96
2026-01-27	ADPT	-20.04	-1.58	5.96
2026-01-28	ADPT	-20.04	-1.58	6.14
2026-01-29	ADPT	-20.04	-1.58	6.14
2026-01-30	ADPT	-20.04	-1.58	6.14
2026-02-02	ADPT	-20.04	-1.60	6.14
2026-02-03	ADPT	-20.04	-1.60	6.14
2026-02-04	ADPT	-20.04	-1.60	6.14
2026-02-05	ADPT	-21.86	-1.60	6.14
2026-02-06	ADPT	-21.86	-1.60	6.14
2026-02-09	ADPT	-21.88	-0.38	6.13
2026-02-10	ADPT	-22.40	-0.38	6.13
2026-02-11	ADPT	-22.40	-0.38	6.14
2026-02-12	ADPT	-22.40	-0.38	6.14
2026-02-13	ADPT	-22.40	-0.38	6.14
2026-02-17	ADPT	-22.40	6.31	6.14
2026-02-18	ADPT	-22.40	6.31	6.14
2026-02-19	ADPT	-22.40	6.31	6.14
2026-02-20	ADPT	-22.40	6.31	6.14
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

-0.16

Avg. EPS Est. Next Quarter

-0.13

Insider Transactions

-22.4

Institutional Transactions

6.31

Beta

2.2

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

75.6

Max Drawdown 5-Year %

-96.3

Target Price

20.86

P/E

Forward P/E

PEG

P/S

8.38

P/B

10.68

P/Free Cash Flow

EPS

-0.4

Average EPS Est. Cur. Y

-0.48

EPS Next Y. (Est.)

-0.27

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-21.48

Relative Volume

0.71

Return on Equity vs Sector %

-68

Return on Equity vs Industry %

-50.5

EPS 1 7Days Diff

EPS 1 30Days Diff

0.11

EBIT Estimation

Adaptive Biotechnologies Corpor

Sector: Healthcare

Industry: Biotechnology

Employees:

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. It has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

stock quote shares ADPT – Adaptive Biotechnologies Corporation Stock Price stock today

news today ADPT – Adaptive Biotechnologies Corporation stock forecast ,stock prediction 2023 2024 2025

marketwatch ADPT – Adaptive Biotechnologies Corporation yahoo finance google finance

stock history ADPT – Adaptive Biotechnologies Corporation invest stock market

stock prices ADPT premarket after hours

ticker ADPT fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: ADPT

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y